| [1] | Ji WeiJia, Yan XueBing. Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2019, 35(2): 309-314. doi: 10.3969/j.issn.1001-5256.2019.02.013 |
| [2] | Yang CaiXia. Immune tolerance after drug withdrawal in a patient with chronic hepatitis B receiving PEG- IFNα- 2a treatment[J]. Journal of Clinical Hepatology, 2017, 33(1): 160-162. doi: 10.3969/j.issn.1001-5256.2017.01.035 |
| [3] | Wu XiaoLi. Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2017, 33(12): 2311-2315. doi: 10.3969/j.issn.1001-5256.2017.12.011 |
| [4] | Lu: Ying, Chen XiaoRong. Clinical effect of 24-week TDF versus ADV sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to 48-week pegylated interferon-α-2a treatment[J]. Journal of Clinical Hepatology, 2016, 32(11): 2066-2069. doi: 10.3969/j.issn.1001-5256.2016.11.010 |
| [5] | Yang Long, Yang Yang, Jiang XueHua, Chen ZhiYong. Efficacy of peginterferon α- 2a in treatment of chronic hepatitis B resistant to multiple nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(4): 691-694. doi: 10.3969/j.issn.1001-5256.2016.04.016 |
| [6] | Peng MeiJuan, Wang Wei, Yang XiaoFei, Hao ChunQiu, Bai XueFan, Jia ZhanSheng, Lian JianQi, Zhang Ye. Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 682-686. doi: 10.3969/j.issn.1001-5256.2016.04.014 |
| [7] | Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015 |
| [8] | Liu YunHua, Li Zhen, Liu Li, Peng Dan, Li WeiKun, Chang LiXian, Jia Ting, Yang YongRui, Li HuiMin, Wang LiQian. Clinical study of pegylated interferon α-2a in treatment of children with HBe Ag-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 193-197. doi: 10.3969/j.issn.1001-5256.2015.02.012 |
| [9] | Liu ZhiHua, He HaiTang, Hu Jing, Fu QunXiang, Luo KangXian. Efficacy of pegylated interferon α-2a in HBe Ag-negative chronic hepatitis B patients and its influencing factors[J]. Journal of Clinical Hepatology, 2015, 31(5): 697-701. doi: 10.3969/j.issn.1001-5256.2015.05.016 |
| [10] | Zhang SuMei, Xie YuMei, Zhang Ying, Guo YongHong, Wei Xin, Jiang Na, Zhou Yun, Jia ZhanSheng. Potential of G-CSF supplementation to counter the neutrophil effects of standard PEG-IFNα plus ribavirin combination therapy for treating HCV-related cirrhosis [J]. Journal of Clinical Hepatology, 2013, 29(5): 348-351. |
| [11] | Lu JianGuo. Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(12): 922-925. doi: 10.3969/j.issn.1001-5256.2013.12.012 |
| [12] | Pan Lei, Wei Xin, Xie YuMei, Hao ChunQiu, Wang JiuPing, Jia ZhanSheng, Bai XueFan. Anti-viral therapy with pegylated interferon alpha-2a plus ribavirin in patients co-infected with HBV and HCV[J]. Journal of Clinical Hepatology, 2011, 27(1): 84-85+95. |
| [13] | Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(1): 86-88. |
| [14] | Wei Xin, Xie YuMei, Chen Lin, Pan Lei, Hao ChunQiu, Wang JiuPing, Bai XueFan, Jia ZhanSheng. Antiviral therapy with pegylated interferon alpha-2a plus ribavirin in patients with HCV related cirrhosis and to establish the grading for standard therapy[J]. Journal of Clinical Hepatology, 2011, 27(1): 89-92. |
| [15] | Zheng YingYing, Fan XiaoHong, Wang LiFen, Tian Di, Huo Na, Lu HaiYing, Wu ChiHong, Xu XiaoYuan, Wei Lai. Efficacy and side effects of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(8): 821-823. |
| [16] | Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419. |
| [17] | Zhao Ping, Wang JiangBin, Jiao Jian. Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features[J]. Journal of Clinical Hepatology, 2010, 26(4): 374-376. |
| [18] | Cheng QianGang, Zhao HaiHong. Clinlical effect and safety of PegIFN α-2a in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(6): 424-426. |
DownLoad: